Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of West Pharmaceutical Services, Inc.. A complete text table follows the diagram.
High-value stoppers, seals, containment systems and self-injection devices become qualified into therapies long before they reach a patient
Swipe to explore
The segment split is exact. Because product-category percentages are approximate and the exact West Vantage segment amount is separately available, the $694.3 million Proprietary Products total is allocated in the filing's relative 48:15:19 proportions and rounded to one decimal: $406.4 million, $127.0 million and $160.9 million.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Injectable-drug systems sales | 1 | $845M | Contain, protect and deliver therapies |
| Proprietary products | 2 | $694M | Qualified packaging and delivery platforms |
| West Vantage | 2 | $151M | Design, manufacture and assemble devices |
| High-value components | 3 | $406M | Modeled from filing mix; stoppers and seals |
| High-value delivery devices | 3 | $127M | Modeled; self-injection platforms |
| Standard packaging | 3 | $161M | Modeled; established containment products |
| From | To | Value |
|---|---|---|
| Injectable-drug systems sales | Proprietary products | $694M |
| Injectable-drug systems sales | West Vantage | $151M |
| Proprietary products | High-value components | $406M |
| Proprietary products | High-value delivery devices | $127M |
| Proprietary products | Standard packaging | $161M |